Inhibiting autophagy enhanced mitotic catastrophe-mediated anticancer immune responses by regulating the cGAS-STING pathway

Cancer Letters, Journal Year: 2024, Volume and Issue: 586, P. 216695 - 216695

Published: Feb. 5, 2024

Language: Английский

---

Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: Sept. 21, 2023

Targeted immunotherapies have emerged as a transformative approach in cancer treatment, offering enhanced specificity to tumor cells, and minimizing damage healthy tissues. The targeted treatment of the immune system has become clinically applicable, demonstrating significant anti-tumor activity both early late-stage malignancies, subsequently enhancing long-term survival rates. most frequent therapies for are executed through utilization checkpoint inhibitor antibodies chimeric antigen receptor T cell treatment. However, when using immunotherapeutic drugs or combined treatments solid tumors like osteosarcoma, challenges arise due limited efficacy induction severe cytotoxicity. Utilizing nanoparticle drug delivery systems target tumor-associated macrophages bone marrow-derived suppressor cells is promising attractive approach. This because these marrow often exert immunosuppressive effects microenvironment, promoting progression, metastasis, development resistance. Moreover, given propensity myeloid engulf nanoparticles microparticles, they logical therapeutic targets. Therefore, we discussed mechanisms nanomedicine-based enhancement therapy targeting how related strategies well adapt immunotherapy from perspectives such immunogenic death with nanoparticles, regulating proportion various cellular subgroups macrophages, interaction ligands, activating immunostimulatory signaling pathways, altering epigenetics, modulating intensity immunostimulation. We also explored clinical implementations grounded on nanomedicine.

Language: Английский

---

Construction of an Immunogenic Cell Death-Related Gene Signature and Genetic Subtypes for Predicting Prognosis, Immune Microenvironments, and Drug Sensitivity in Hepatocellular Carcinoma

Journal of Inflammation Research, Journal Year: 2024, Volume and Issue: Volume 17, P. 2427 - 2444

Published: April 1, 2024

Purpose: Immunogenic cell death (ICD) is a type of regulated that modifies the immune response by releasing DAMPs or danger signals.Herein, we aimed to develop an ICD-related predictive model for patients with hepatocellular carcinoma (HCC) and investigate its applicability predicting prognostic outcomes immunotherapeutic responses.Methods: Differentially expressed genes ICD were identified in HCC normal liver samples.A risk nomogram containing clinicopathological features created.To validate effectiveness model, external dataset was used.Clinical characteristics, prognosis, tumor mutation burden, microenvironments, biological function chemotherapeutic drug sensitivity evaluated different genetic subtypes groups.Results: A total 35 (ICDRGs) between samples, 11 which significantly associated overall survival (OS) patients.Four formed eight ICDRGs selected model.The scores shown be independent factor positively correlated pathological severity.Patients high-risk group had higher frequency TP53 mutations, increased expression checkpoints human leukocyte antigen genes.The inhibitory concentrations drugs differed populations. Conclusion:In this study, developed ICDRG demonstrated outcomes, responses patients.ICDRGs are expected used as novel biomarkers medical decision-making HCC.

Language: Английский

---

PDL1/HER2‐Targeted Lipid‐Encapsulated Oxygen Nanobubbles Combined with Photodynamic Therapy for HER2⁺ Breast Cancer Immunotherapy

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 7, 2024

Abstract Programmed death (PD) 1/PD ligand 1 (PDL1) inhibitors are immune checkpoint (ICIs) that may facilitate HER2‐positive breast cancer treatment; however, their clinical efficacy remains elusive. Oxygen‐enhanced photodynamic therapy (PDT) increases immunogenic cell (ICD), providing a promising strategy to render the tumor microenvironment more sensitive ICIs. Lipid‐encapsulated oxygen nanobubbles (Lipo‐NBs‐O 2 ) obtained using (NBs) water for delivery in vivo can enhanced PDT. Here, dual‐receptor targeted Lipo‐NBs‐O (DRT@Lipo‐NBs‐O is prepared by modifying with anti‐PDL1 scFv and fusion protein anti‐HER2 scFv‐tandem‐repeat cytochrome c (anti‐HER2‐nCyt ). Copper phthalocyanine photosensitizer (PS). DRT@Lipo‐PS‐NBs‐O plus near‐infrared irradiation leads robust ICD induction, increasing DC activation CD8 + T‐cell numbers. Modification improves distribution of plays ICI role, invigorating T cells boosting effects immunotherapy. Oxygen supplied through reduces P‐glycoprotein expression. Enhanced PDT Cyt cause death, thereby reducing burden. Under dual receptor targeting laser local irradiation, become subject combination PDT, ICD, ICIs, apoptosis; this effectively suppresses growth metastasis. affords multidrug alleviate cancer.

Language: Английский

---

Engineered Carrier-Free Nanosystem-Induced In Situ Therapeutic Vaccines for Potent Cancer Immunotherapy

ACS Applied Materials & Interfaces, Journal Year: 2024, Volume and Issue: 16(36), P. 47270 - 47283

Published: Aug. 27, 2024

In situ vaccines that can stimulate tumor immune response have emerged as a breakthrough in antitumor therapy. However, the immunosuppressed microenvironment and insufficient infiltration of cells lead to ineffective immunity. Hence, biomimetic carrier-free nanosystem (BCC) induce synergistic phototherapy/chemotherapy-driven was designed. A developed using phototherapeutic reagents CyI celastrol raw materials. vitro vivo studies shown under NIR light irradiation, BCC-mediated photo/chemotherapy not only accelerates release drugs deeper parts tumors, achieving timing light-controlled drug delivery result cell apoptosis, but also effectively stimulates vaccine, which could invoke long-lasting immunity inhibit metastasis eliminate distant tumor. This therapeutic strategy holds promise for priming robust innate adaptive responses, arresting cancer progression, inducing dormancy.

Language: Английский

---

Dual roles of human endogenous retroviruses in cancer progression and antitumor immune response

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2024, Volume and Issue: 1879(6), P. 189201 - 189201

Published: Oct. 18, 2024

Language: Английский

---

Synergistic action of gemcitabine and celecoxib in promoting the antitumor efficacy of anti-programmed death-1 monoclonal antibody by triggering immunogenic cell death

Translational Cancer Research, Journal Year: 2024, Volume and Issue: 13(6), P. 3031 - 3045

Published: June 1, 2024

Emerging evidence suggests that immunogenic chemotherapy not only kills tumor cells but also improves the immune-suppressive microenvironment by inducing cell death (ICD), leading to sustained anti-tumor effects. The lack of ICD inducers explored in lung cancer necessitates investigation into new for this context, therefore, study aims explore whether gemcitabine (GEM) and celecoxib can activate progress tissue.

Language: Английский

---

Pyroptosis and chemical classification of pyroptotic agents

Molecular Diversity, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 24, 2024

Abstract Pyroptosis, as a lytic-inflammatory type of programmed cell death, has garnered considerable attention due to its role in cancer chemotherapy and many inflammatory diseases. This review will discuss the biochemical classification pyroptotic inducers according their chemical structure, mechanism, these targets. A structure-activity relationship study on is revealed based surveyed inducer chemotherapeutics. The shared features structures current agents were displayed, including an essential cyclic head, vital linker, hydrophilic tail that significant for π-π interactions hydrogen bonding. presented structural open way design new hybridized classes or scaffolds potent future, which may represent solution apoptotic-resistance dilemma along with synergistic chemotherapeutic advantage. Graphical

Language: Английский

---

Revealing the mechanism of natural product-induced immunogenic cell death: opening a new chapter in tumor immunotherapy

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 9, 2024

This review underscores the role of natural products in inducing immunogenic cell death (ICD) as a key strategy tumor immunotherapy. It reveals that can activate ICD through multiple pathways—apoptosis, autophagy, pyroptosis, and necroptosis—leading to release danger-associated molecular patterns (DAMPs), dendritic activation, improved antigen presentation, which together stimulate potent anti-tumor immune response. The study also demonstrates enhanced therapeutic potential combining with checkpoint inhibitors. With focus on translating preclinical findings into clinical practice, this consolidates recent discoveries suggests future research paths, offering both theoretical insights practical guidance for advancing cancer

Language: Английский

---

Salmonella-based therapeutic strategies: improving tumor microenvironment and bringing new hope for cancer immunotherapy

Medical Oncology, Journal Year: 2024, Volume and Issue: 42(1)

Published: Dec. 12, 2024

Language: Английский

---